Evidence map›Paper›PMID 19324060›Full record

ArticleLife sciences2009

Protein kinases C isozymes are differentially expressed in human breast carcinomas.

Shadan Ali, Sana Al-Sukhun, Bassel F El-Rayes, Fazlul H Sarkar, Lance K Heilbrun, Philip A Philip

Abstract read
In one paragraph

Article in Life sciences, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Shadan AliDivision of Hematology/Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, United States.
Sana Al-Sukhun
Bassel F El-Rayes
Fazlul H Sarkar
Lance K Heilbrun
Philip A Philip
Wayne State University · USThe Barbara Ann Karmanos Cancer Institute · US

Funding

Tumor Biology and Microenvironment (Program 1)P30CA022453 · NCI · WAYNE STATE UNIVERSITY · PI Julie Lynn Boerner · 1985 to 2026
$68.4M
Enhancing neoadjuvant chemotherpay responses with targeted T cellsR01CA140314 · NCI · WAYNE STATE UNIVERSITY · PI BEPLER, GEROLD · 2010 to 2015
$2.5M
NCI NIH HHS P30 CA022453NCI NIH HHS R01 CA140314
6 · The paper itself

Abstract

aimsThe protein kinase C (PKC) family of enzymes has been implicated in cellular proliferation, differentiation, and apoptosis. However, the distribution of specific PKC isoforms with varying functions in normal and malignant human tissues remains to be determined. The objective of this study was to investigate the expression of certain PKC isoforms (alpha, betaI, betaII, epsilon) in human breast cancer specimens relative to adjacent uninvolved tissue (n=24) and in the normal breast tissue obtained from patients undergoing reduction mammoplasty (n=12). MAIN

methodsWestern blot analysis using PKC isoform specific antibodies was performed on tissue extracts from breast tumors, adjacent uninvolved tissues, and reduction mammoplasty tissues. KEY

findingsMean levels of cytosolic and membrane PKC-alpha, PKC-betaI, and PKC-betaII were significantly higher in the cancer specimens than in the adjacent uninvolved breast tissues (Wilcoxon signed-ranks test; P<0.05 for each, after adjustment for multiple comparisons). There was a notably higher mean level of membrane PKC-betaII isozyme in Her-2 positive and in poorly differentiated tumors. No significant differences were observed when normal tissue adjacent to tumor was compared to breast tissue obtained from reduction mammoplasty specimens. SIGNIFICANCE: Higher level of PKC-alpha, PKC-betaI, and PKC-betaII in cancer specimens and higher level of PKC-betaII in Her-2 positive tumors require further exploration of the intracellular pathways involving PKC-alpha and -beta isoforms in breast cancer because both could be specific targets for the development of new therapies and for the prevention and treatment of this disease.

Indexed as

ApoptosisBlotting, WesternBreast NeoplasmsCell DifferentiationCell ProliferationErb-b2 Receptor Tyrosine KinasesFemaleHumansImmunohistochemistryIsoenzymesProtein Kinase CReceptors, EstrogenERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesIsoenzymesProtein Kinase CReceptors, Estrogen

Identifiers

PMID19324060
PMCPMC3822902
OpenAlexW2003100025

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.